Assessment of Lymph Nodes and Prostate Status Using Early Dynamic Curves with 18F-Choline PET/CT in Prostate Cancer by Cédric Mathieu et al.
ORIGINAL RESEARCH
published: 09 September 2015
doi: 10.3389/fmed.2015.00067
Edited by:
Thierry M. L. B. Vander Borght,
CHU Dinant Godinne, Belgium
Reviewed by:
Maria Mathew D’Souza,
Institute of Nuclear Medicine and
Allied Sciences, India
Baljinder Singh,
Post Graduate Institute of Medical
Education and Research, India
*Correspondence:
Cédric Mathieu,
Department of Nuclear Medicine, ICO
Cancer Center, Boulevard Jacques
Monod, Saint Herblain 44805, France
cedric.mathieu@chu-nantes.fr
Specialty section:
This article was submitted to Nuclear
Medicine, a section of the journal
Frontiers in Medicine
Received: 29 April 2015
Accepted: 27 August 2015
Published: 09 September 2015
Citation:
Mathieu C, Ferrer L, Carlier T,
Colombié M, Rusu D,
Kraeber-Bodéré F, Campion L and
Rousseau C (2015) Assessment of
lymph nodes and prostate status
using early dynamic curves with
18F-choline PET/CT in prostate
cancer.
Front. Med. 2:67.
doi: 10.3389/fmed.2015.00067
Assessment of lymph nodes and
prostate status using early dynamic
curves with 18F-choline PET/CT in
prostate cancer
Cédric Mathieu1,2*, Ludovic Ferrer 3,4, Thomas Carlier 2,3, Mathilde Colombié1,
Daniela Rusu1, Françoise Kraeber-Bodéré1,2,3, Loic Campion5 and Caroline Rousseau1,3
1 Department of Nuclear Medicine, ICO Cancer Center, Saint Herblain, France, 2 Department of Nuclear Medicine, University
Hospital, Nantes, France, 3 Centre Régional de Recherche en Cancérologie Nantes/Angers, U892, CNRS UMR 6299, INSERM,
Nantes, France, 4 Department of Medical Physics, ICO Cancer Center, Saint Herblain, France, 5 Department of Statistics, ICO
Cancer Center, Saint Herblain, France
Introduction: Dynamic image acquisition with 18F-Choline [fluorocholine (FCH)] PET/CT
in prostate cancer is mostly used to overcome the bladder repletion, which could obstruct
the loco-regional analysis. The aim of our study was to analyze early dynamic FCH
acquisitions to define pelvic lymph node or prostate pathological status.
Material and methods: Retrospective analysis was performed on 39 patients for initial
staging (n=18), or after initial treatment (n=21). Patients underwent 10-min dynamic
acquisitions centered on the pelvis, after injection of 3–4MBq/kg of FCH. Whole-body
images were acquired about 1 h after injection using a PET/CT GE Discovery LS (GE-
LS) or Siemens Biograph mCT (mCT). Maximum and mean SUV according to time were
measured on nodal and prostatic lesions. SUVmean was corrected for partial volume
effect (PVEC) with suitable recovery coefficients. The status of each lesion was based on
histological results or patient follow-up (>6months). A Mann–Whitney test and ANOVA
were used to compare mean and receiver operating characteristic (ROC) curve analysis.
Results: The median PSA was 8.46 ng/mL and the median Gleason score was 3+4.
Ninety-two lesions (43 lymph nodes and 49 prostate lesions) were analyzed, including
63 malignant lesions. In early dynamic acquisitions, the maximum and mean SUV were
significantly higher, respectively, on mCT and GE-LS, in malignant versus benign lesions
(p<0.001, p<0.001). Mean SUV without PVEC, allowed better discrimination of benign
from malignant lesions, in comparison with maximum and mean SUV (with PVEC), for
both early and late acquisitions. For patients acquired on mCT, area under the ROC curve
showed a trend to better sensitivity and specificity for early acquisitions, compared with
late acquisitions (SUVmax AUC 0.92 versus 0.85, respectively).
Conclusion: Assessment of lymph nodes and prostate pathological status with early
dynamic imaging using PET/CT FCH allowed prostate cancer detection in situations
where proof of malignancy is difficult to obtain.
Keywords: 18F-choline, prostate cancer, dynamic curves, early acquisition, pathological status
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Introduction
Prostate cancer is the most common cancer in men over 50 years,
and the third highest cause of death by cancer. Initial staging is
reserved for tumors with intermediate or high risk according to
the D’Amico classification (1). Recurrence of prostate cancer after
treatment is common and occurs in 20–50% of cases at 10 years
after radical prostatectomy, and in 30–40% after radiotherapy
(2, 3). Management of biological relapse after curative treatment
is a real diagnostic and therapeutic challenge. Hormone ther-
apy is currently the standard palliative treatment and resistance
inevitably occurs after 2–5 years (4).
In patients with intermediate or high risk, local extension,
nodal, or bone metastasis, have major prognostic and therapeutic
implications (4). Bone scans are recommended for patients at
intermediate or high risk of progression. MRI has a major role
for local extension, or location of prostate cancer after negative
biopsies (5–7). Abdominal and pelvic CT can be used in order to
highlight nodalmetastases (8). However, imaging is supplanted by
extent lymphadenectomy, which is recommended before prosta-
tectomy or radiotherapy for intermediate and high risk prostate
cancer to precisely evaluate the nodal status (9). The sentinel
lymph node technique is being evaluated to guide surgeons to
ensure optimal quality of dissection (10).
In prostate cancer, fluorocholine (FCH) PET/CT is indicated
as an alternative to FDG PET/CT relevant to mitotic and choline
kinase activities (11, 12). FCH is a highly sensitive and specific
radiopharmaceutical for the initial staging of prostate cancer
(intermediate or high risk tumors), or suspicion of recurrence
(13–16). In most cases, PET/CT is performed in two phases (17).
The first is a kinetic step centered on the pelvis to achieve the
regional analysis before bladder repletion. The second consists of
whole-body image acquisition 1 h post-injection.
The aim of our study was to evaluate the potential benefit of
early kinetic FCH PET/CT for discriminating malignant from
benign lymph node or prostate lesions, whose status has been
proven by histological analysis or patient follow-up.
Materials and Methods
Population
Retrospective analyses were performed on patients with histolog-
ically proven prostatic adenocarcinoma and explored for initial
staging or biochemical recurrence. Recurrence was defined as
two consecutive PSA values of 0.2 ng/mL and above after rad-
ical prostatectomy, or three consecutive increasing PSA values
above the previous PSA nadir measured at 3-month interval
after radiotherapy. Patients had at least one focal FCH uptake
in pelvic lymph nodes or in the prostate. All patients had an
initially negative or equivocal conventional imaging, including
bone scan, CT, and/or MRI. For each patient, we collected age,
serum PSA, date of initial diagnosis, Gleason score, topography
of prostate cancer, initial treatment, and time to recurrence. We
obtained informed consent from all patients allowing the use of
their clinical data for research purposes under a protocol approved
in our institution.
Acquisition and Interpretation of PEC/CT
After 6 h of fasting, 3–4MBq/kg of FCHwere injected when start-
ing PET/CT acquisition. Acquisition was realized in two phases.
First a 10-min kinetic acquisition in list mode centered on the
pelvis was acquired, followed by whole-body image acquisition at
60min. Examinations were performed on two different PET/CT
instruments, a GE Discovery LS (GE-LS) (GE Medical System,
Waukesha WI, USA) and a Siemens Biograph mCT 40 (mCT)
(Siemens, Erlanger, Germany). Images were reconstructed by iter-
ative OSEM reconstruction with two iterations and 28 subsets
associated with a 2D Gaussian filter (FWHM 5.45mm) for GE-
LS and OP-OSEM-PSF TOF with 3 iterations and 21 subsets
associated with a 3D Gaussian filter (2mm FWHM) for mCT.
Maximum and mean standard uptake values (SUVmax and
SUVmean) were measured on late images in every prostatic or
pelvic nodal lesion. Dynamic curves were built for each lesion,
measuring the SUVmax and SUVmean every minute in the first
10min. To delineate the tumor contours, we used a system-
specific contrast-oriented algorithm proposed by Nestle (18),
using the following formula:
SUVthreshold = (k SUVmax) + SUVbackground
The SUVbackground was defined as the SUVmean in the gluteus
maximus, and k was a system-specific constant determined by
phantom acquisitions for each PET/CT camera. A correction of
partial volume effect (PVEC) on SUVmean was performed with
suitable recovery coefficients (19).
Gold Standard and Statistical Analyses
Lymph node or prostate lesions preferentially confirmed by his-
tology were considered (prostatectomy results, lymph node dis-
section, or prostate biopsies). In other cases, concordant imaging
(CT orMRI) or PSA decrease after targeted radiotherapy was also
used to confirm lesion status. FCH uptake in the inguinal region
was interpreted as reactive inflammatory lymph node as described
in the literature (20). For patients with prostatic histological proof
(biopsy or resection), the agreement between PET images and his-
tology was evaluated by comparison with the detailed histological
report. Statistical analysis consisted of a comparison of repeated
averages between benign and malignant lesions using an ANOVA
for early acquisitions. For late acquisitions, the SUV of benign
and malignant lesions were compared by comparing averages
(non-parametric Mann–Whitney test). SUV between the end of
the early acquisition (10min) and the late acquisition (60min)
was compared using a paired t-test. Early and late acquisitions
were compared using a receiver operating characteristic (ROC)
curve, only for patients acquired on mCT (n= 71). The tests were
performed bilaterally with a limit of 5% significance (p 0.05).
The software used was SPSS 18 and Stata 13.1.
Results
Patients and Lesions
We identified 39 patients from September 2008 to January 2014
with FCH uptake in 49 prostatic and 43 nodal lesions. Median
Frontiers in Medicine | www.frontiersin.org September 2015 | Volume 2 | Article 672
Mathieu et al. Dynamic 18F-choline in prostate cancer
age was 73 years and median PSA at PET time was 8.46 ng/mL
(2.02–172.6). Among the 21 patients with biochemical recur-
rence, initial treatment was a prostatectomy for 38% (8/21)
of them, and the median time to recurrence was 54.8months
(12–195). The median PSA doubling time was 8.2months
(1.7–24.7). Four patients were treated with hormone therapy at
the time of PET (10.2%). Patient characteristics are presented in
Table 1.
Within the 39 patients explored, 19 patients (49%) had isolated
prostatic lesions, 8 (20%) isolated nodal lesions, and 12 (31%)
had both. Histological results were available for 96.7% (30/31)
of patients with prostatic lesions and for 40% (8/20) of patients
with nodal lesions (lymph node dissection). For one patient with
histologically unconfirmed prostatic lesions, PSA decrease after
targeted radiotherapy was considered as a proof of disease. For
the 12 patients with histologically unproven lymph node lesions,
malignancy was assessed by a concordant imaging between CT
and MRI in five cases (25%), PSA decrease after targeted radio-
therapy in three cases (15%) or inguinal lymph node loca-
tion in four cases (20%). Lesion characteristics are presented in
Table 2.
TABLE 1 | Description of patient characteristics (n= 39).
Initial staging n= 18
(Min–Max)
Recurrence n= 21
(Min–Max)
Median age (years) 70.5 (51–78) 74 (55–84)
Median PSA at PET (ng/mL) 11.5 (3.5–172.6) 5.23 (2.02–14.95)
Gleason score
6 3 5
7 9 13
8–9 6 2
Unknown 0 1
Initial stage
T1 7 3
T2 6 10
T3 3 5
Unknown 2 3
Previous treatment
S NA 2
S+R 5
S+HT 1
R 10
R+HT 1
HT 2
S, surgery; S+R, Surgery+Radiotherapy; R+HT, Radiotherapy+Hormone Therapy;
HT, hormone therapy; NA, not applicable.
TABLE 2 | Description of lesion characteristics (n= 92) in the 39 patients.
Prostatic lesions number (%) Nodal lesions number (%)
Per patient analysis Per lesion analysis Per patient analysis Per lesion analysis
Number 31 49 20 43
Histological proof 30 (97%) 48 (98%) 8 (40%) 14 (33%)
Concordant imaging 0 (0%) 0 (0%) 5 (25%) 14 (33%)
PSA decrease after RTE 1 (3%) 1 (2%) 3 (15%) 7 (16%)
RTE, radiotherapy.
Within the 49 prostatic lesions, 38 were malignant (77.6%), and
28 (57.1%) were identified in patients referred for initial stag-
ing. Forty-three nodal lesions were explored, 25 were malignant
(58.1%) and 18 (41.8%) were identified in patients referred for
initial staging. The location of the 25 malignant lymph nodes was
as follows: common iliac for 5 (20%), external iliac for 14 (56%),
internal iliac for 2 (8%), obturator fossa for 1 (4%), and pre-sacral
for 3 (12%). Benign lymph nodes were found in the common iliac
area for one (6%), external iliac for five (28%), and inguinal node
for 12 (66%).
Early Kinetic of Lymph Node and Prostate
Lesions
The mean SUVmax on the early dynamic acquisitions was sig-
nificantly higher for malignant versus benign lesions, respec-
tively, on mCT (n= 71) and on GE-LS (n= 21) (p< 0.001 and
p< 0.001). Malignant lesions showed intense FCH uptake, with
a maximum level of SUVmax almost reached at the second minute
post-injection, followed by a plateau. Benign lesions showed a less
intense uptake. Themean SUVmax in the plateau was, respectively,
on mCT and on GE-LS about 12 and 8 for malignant lesions and
5 and 3 for benign lesions (Figures 1 and 2). The results were
confirmed with SUVmean with significantly higher FCH uptake in
malignant lesions (with and without PVEC).
Analysis of 60min Post-Injection Images and
Comparison to the Early Kinetic Results
On mCT (n= 71), the mean SUVmax in the late acquisition was
significantly higher in malignant lesions versus benign lesions,
11.1 versus 3.8 (p< 0.001), and also on LS-GE PET (n= 21) 8
versus 2.7 (p< 0.001). There was a significant decrease of the
average SUVmax between the end of the early acquisition and
late acquisition of 13% for malignant lesions (12.8 versus 11.1,
p< 0.001), and 19% for benign lesions (4.7 versus 3.8, p= 0.02).
On mCT (n= 71), the optimal SUV threshold that maximized
both sensitivity and specificity in early acquisitions was obtained
at 8min post-injection. SUVmax ROC curve analysis showed bet-
ter area under the curve (AUC) for the early acquisition at 8min
versus late acquisition (Figure 3) (0.92 versus 0.85, respectively).
In the early acquisitions, SUVmean displayed the best AUC in
comparison with SUVmax and SUVmean with PVEC (0.97 versus
0.92 and 0.91, respectively). The same results were found for
late acquisitions with a superiority of SUVmean without PVEC.
Optimal threshold and data for SUVmean with and without PVEC
are summarized in Table 3.
Frontiers in Medicine | www.frontiersin.org September 2015 | Volume 2 | Article 673
Mathieu et al. Dynamic 18F-choline in prostate cancer
FIGURE 1 | Early dynamic curves (first 10min) for benign and
malignant lesions acquired by mCT PET/CT (n= 71).
FIGURE 2 | (A) Axial early FCH PET/CT acquisition (mCT PET/CT instrument),
(B) maximum intensity projection (MIP) in the same patient. Patient evaluated
before initial surgery with a prostatic adenocarcinoma, Gleason 3+ 4, PSA at
10 ng/mL. Histological analysis showed a left prostatic adenocarcinoma (red
curve) while the right lobe was free of disease (green curve): statistically
significant difference of tracer uptake between the two lobes was obtained.
Discussion
We conducted a retrospective study with early dynamic acqui-
sitions of FCH PET/CT in patients explored for initial stag-
ing or suspicion of recurrence of prostate cancer. To the best
of our knowledge, this is the first study to assess the kinetic
uptake of the radiopharmaceutical with 1min step images to
discriminate benign from malignant lesions, and explore the
potential benefit that could be provided by PVEC correction for
SUVmean.
There are few published data on the contribution of dynamic
acquisitions, and most involve small cohorts of patients. While
it is known that an initial dynamic acquisition is useful in
differentiating prostatic lesions from the urinary tract (21), the
optimal image acquisition time remains uncertain. For prostatic
lesions, Kwee et al. (17) conducted a prospective study in 26
patients with an early whole-body imaging at 7min post-injection
associated with a step on the pelvis 1 h post-injection. They
showed that benign lesions could be quickly differentiated from
malignant lesions with higher uptake and an increased SUVmax by
14% over time. Because they built a curve with two independent
measurements of SUV, they could not precisely define the time
to reach maximum activity. Steiner et al. (22) in a retrospective
study of 15 lesions in 11 patients achieved a FCH PET/CT in 3
phases (dynamic 10min, immediately followed by a whole body
and a late acquisition on pelvis at 1 h post-injection). They found
that benign lesions could be quickly differentiated frommalignant
lesions, which show higher uptake and an increasing SUVmax
until the 14th minute. In our study, the dynamic acquisition in
list mode allowed us to determine a maximum activity reached
in about the third minute post-injection, followed by an initial
plateau and a discrete reduction of SUV, especially for benign
lesions.
Dynamic acquisitions with choline labeled with 18Fluorine are
more appropriate than with 11Carbon, because of the short half-
life of 11Carbon (20min). However, a prospective study using
11C-Choline in 56 patients performed with two successive whole-
body acquisitions at about 3–5 and 20min post-injection, demon-
strated dual phase acquisition was useful in distinguishing benign
from malignant lesions (23). Nevertheless, they used a different
radiopharmaceutical and they did not acquire dynamic, therefore
making comparisons to our study difficult.
The behavioral differences between malignant and benign
lesions, whether for prostatic or nodal lesions, encourage the use
of ROC curves to define optimal thresholds to discriminate the
lesions. For prostatic lesions, Kwee et al. (17) found an AUC
of 0.81 at 7min and 0.92 for late acquisition at 1 h, without
defining a threshold. Oprea-Lager et al. (20) only examined nodal
lesions, with an AUC of 0.93 at 30min for the SUVmax and 0.92
for the SUVmean. They determined thresholds for lymph nodes
at 2.32 and 1.66 on late acquisitions for SUVmax and SUVmean,
respectively. In our study, we found similar AUC using SUVmax
for early and late acquisitions (0.92 and 0.85, respectively). Our
optimal SUVmax thresholds were 6.1 and 4.3 on early and late
acquisitions, respectively, which allowed a sensitivity of 89.8
and 77.5%, and a specificity of 90.9 and 77.3%. We observed
superior performance for SUVmean than SUVmax, for both early
and late acquisitions. We also observed a better AUC for the
early acquisition at 8min versus late acquisition. Few studies
explored the use of SUVmean, especially for response to ther-
apy studies with a high impact of PVE correction. Neverthe-
less, a precise and robust delineation of tumor functional vol-
ume as used in our study, this index seems more relevant than
SUVmax. SUVmax provides only very limited information relating
to radiotracer accumulation, andno information on the associated
tumor uptake distribution or the overall tumor functional volume
(24). A meta-analysis showed better repeatability performance
of SUVmean versus SUVmax and could explain the differences
observed (25).
We acknowledge that our study has some limitations.
First, our acquisitions used two different generation PET/CT
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FIGURE 3 | Receiver operating characteristic curve for distinguishing benign from malignant lesions using SUVmax (A) and SUVmean [(B), without
partial volume effect correction] for patients acquired on mCT (n= 71).
TABLE 3 | Optimal threshold of SUV for distinguishing benign from malignant lesions using SUVmax and SUVmean for patients acquired on mCT (n= 71).
Acquisition Optimal threshold AUC Sensitivity (%) Specificity (%) Accuracy (%)
SUVmax Early 6.1 0.92 89.8 90.9 90.1
Late 4.3 0.85 77.5 77.3 77.5
SUVmean Early 2.5 0.97 98 86.4 94.4
Late 2.4 0.93 89.8 72.7 84.5
SUVmean(PVEC) Early 5.1 0.91 87.8 81.8 85.9
Late 5.0 0.87 83.7 72.7 80.3
instruments. This resulted in significant differences in detection
sensitivity, making it impossible to compare patients acquired
on the two different PET/CT systems. Second, as our study was
based on patients where the malignant or benign status of lesions
was proven, the enrollment was limited but equally important
compared to other literature studies. For prostate lesions, we
obtained a high rate of histological proof; 96.7% of patients had
prostate lesions proven by biopsy or prostatectomy. For lymph
node involvement, histological results were obtained for only 40%
of patients, which was partially due to the difficulty in proposing
systematic lymph node dissection based on PET/CT results. On
the other hand, it was difficult to intraoperatively identify lymph
node lesions detected by PET/CT because most of the time FCH
positive lymph nodes did not correspond to morphologically
increased node volume. Oprea-Lager et al. reported the same
difficulties in obtaining proof for suspected malignant lymph
nodes (20).
Conclusion
Assessment of lymph nodes and prostate pathological status with
early PET/CT FCH dynamic curves was successful in prostate
cancerwhere proof ofmalignancy is difficult to obtain. In addition
to avoiding bladder repletion, dynamic early acquisitions demon-
strated intense and stable FCH uptake from the first minutes post-
injection, and discriminated benign frommalignant lesions either
in prostate or in lymph nodes. SUVmean without correction of
PVEC and early acquisitions may perform better than maximum
SUVmax and late acquisitions, but larger studies are warranted.
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